Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Committee backs efficacy of Dendreon cancer drug
If approved for marketing by the FDA, Provenge would become the first active cellular immunotherapy and the first biologic approved to treat prostate cancer. The FDA will now
If approved for marketing by the FDA, Provenge would become the first active cellular immunotherapy and the first biologic approved to treat prostate cancer. The FDA will now
Globorix is designed to treat diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, Neisseria meningitides serogroups A and C. Globorix will only be sold and used in
If licensed, the vaccine will be indicated for the prevention of cervical cancer and precancerous lesions associated with the most common cancer-causing human papillomavirus types. For this candidate
Reverse genetics is a method by which viruses such as influenza can be generated entirely from segments of DNA. For potential pandemic influenza vaccines, reverse genetics can be
The phase I/II study indicated that Baxter’s H5N1 candidate vaccine is highly immunogenic at low doses, and induces substantial levels of cross immunity against widely divergent H5N1 strains.
Clinical Data said it plans to offer the 454 GS FLX ‘Next Generation’ sequencing technology as a fee-for-service offering to clients worldwide and has said it will collaborate
The company plans to use this technology to develop an oral liquid product of its chronic pain drug Kadian. Alpharma said this planned addition to the Kadian product
NeoPharm said it was disappointed by the decision which, if implemented, would significantly delay the introduction of this therapy to the market. However, the Office of Oncology has
The phase I trial program, designed to assess the safety of the drug candidate HE3286, could support both a phase II study in type 2 diabetes patients, as
The primary goal of the phase I study was to evaluate safety and pharmacokinetic properties of XTL-6865 in patients with chronic hepatitis C. XTL-6865, which targets the E2